Hello Again Market Enthusiast,

Have you checked Galmed Pharmaceuticals (Nasdaq: GLMD) yet? If not, YOU NEED TO NOW.

Galmed Pharmaceuticals (Nasdaq: GLMD) is trading at just ~$1.73, but analysts are targeting $12.00—an insane 594% upside! With a tiny float of just 1.31M shares, this company can move FAST. (1)(3)(4)(5)

The momentum is building—don’t get left behind. ⏳

(8)

🔥 The Micro-Float Advantage:

With only 1.31M shares floating and 1.66M shares outstanding, GLMD has one of the TINIEST floats in the biotech sector! (2)

This creates a perfect storm for dramatic price movement with any positive catalyst!

🧪 Why This Matters RIGHT NOW: (2)

• Micro-Float Power: Only 1.31M shares available to the public means limited supply!
• Minimal Institutional Ownership: Just 3.09% held by institutions = massive room for discovery
• Limited Short Interest: Only 0.30% of float is short, showing minimal bearish sentiment
• Insiders Holding Strong: 1.89% insider ownership shows team confidence

🧬 The Science That's Changing Lives:

Galmed's revolutionary Aramchol™ treatment for NASH (a $21.5 BILLION market with NO approved treatments) is in final Phase III trials. (3)(5)(7)(8)

This isn't speculation – it's science on the verge of a breakthrough!

⏰ The MATH Is Simple But Stunning: (2)(4)(5)(6)

• Analyst target: $12.00
• Potential return: 594%
• Average daily volume: Only 31.59K shares!

When you combine groundbreaking medical science + final clinical stage + micro-float + analyst targets 7X higher than current prices... the potential becomes simply extraordinary!

🌟 Why This Is Flying Under The Radar:

While everyone's distracted by mega-cap tech, Galmed has quietly built an impressive treatment pipeline, secured critical patents until 2039, and positioned themselves to potentially dominate liver disease treatment. 

These are precisely the conditions that create life-changing chances in biotech!

(8)

🔍 What Makes This TRULY Special:

The combination of such a tiny float (1.31M shares) with such minimal institutional ownership (3.09%) creates a rare situation where retail discovery could drive extraordinary momentum when clinical milestones are achieved. (2)(4)

⏱️ Why Timing Is EVERYTHING:

With Phase III results approaching and a price target 594% above Friday's close, those who wait for "confirmation" may miss the most significant early action. (4)(5)

The limited float means price movement could be swift and dramatic when news breaks.

Don't be the one saying "I heard about GLMD at $1.73" when everyone's talking about their medical breakthroughs!

Remember how quickly biotech companies can transform the healthcare landscape? 

With Galmed's micro-float of just 1.31M shares, any positive development could create truly remarkable movement! 🧬🔍

Check out Galmed Pharmaceuticals (Nasdaq: GLMD) now! ⏰

Staying ahead of the curve,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/quote/GLMD/
2. https://finance.yahoo.com/quote/GLMD/key-statistics/
3. https://bit.ly/4bS2x8U
4. https://finance.yahoo.com/quote/GLMD/history/
5. https://bit.ly/3FwFkgy
6. https://bit.ly/3DNGGmD
7. https://bit.ly/41vjbXq
8. https://bit.ly/4bXbRZ9

Momentum Media LLC has not been compensated for today's profile on Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) starting on 3/16/25 and ending on 3/17/25. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.